NSPR Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $0.62
Market Cap (MRQ) $29M
P/E (TTM) -1.0
EPS (TTM) $-0.61
Revenue (TTM) $11M
ROE (TTM) -202.8%
52W Range $1–$3

NSPR Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 5
Ex-date Split Type
April 27, 2021 1-for-15 Reverse
April 1, 2019 1-for-50 Reverse
Oct. 10, 2016 1-for-25 Reverse
Oct. 1, 2015 1-for-10 Reverse
Dec. 21, 2012 1-for-4 Reverse

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$9M
2016-12-31 → 2025-12-31
EPS$-0.76
2022-12-31 → 2025-12-31
Free Cash Flow$-37M
2016-12-31 → 2025-12-31
Net margin-484.1%
2016-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend NSPR 5Y avg Peer Median Verdict
P/E (TTM) -1.05Y avg ≈-2.4 ≈-2.4 · ·
P/S (TTM) 2.75Y avg ≈7.1 ≈7.1 1.6 Overvalued
P/B (MRQ) 0.95Y avg ≈1.2 ≈1.2 0.8 Overvalued
Price / FCF (TTM) -0.75Y avg ≈-2.2 ≈-2.2 · ·
Price / Cash Flow (TTM) -0.75Y avg ≈-2.3 ≈-2.3 · ·
Price / Tangible Book 0.55Y avg ≈1.2 ≈1.2 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 10.2%
Next Report Nov 02, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 14, 2026 $-0.17 $-0.20 16.7%
March 31, 2026 May 12, 2026 $-0.16 $-0.18 12.9%
Dec. 31, 2025 $-0.14 $-0.20 29.0%
Sept. 30, 2025 $-0.17 $-0.20 14.5%
June 30, 2025 $-0.26 $-0.27 2.0%
March 31, 2025 $-0.22 $-0.20 -7.8%
Dec. 31, 2024 $-0.19 $-0.20 4.5%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 18
Metric Trend 202520242023202220212020201920182017201620152014
Revenue $9M$7M$6M$5M$4M$2M$4M$4M$3M$2M$2M$3M
Cost of Revenue $6M$6M$4M$4M$4M$2M$3M$3M$2M$2M$3M$2M
Gross Profit $3M$2M$2M$1M$754.0K$83.0K$756.0K$995.0K$585.0K$102.0K$-296.0K$784.0K
R&D Expense $15M$14M$8M$8M$5M$2M$3M$2M$1M$1M$4M$9M
SG&A Expense $21M$15M$11M$8M$7M$6M$5M$5M$5M$5M$6M$9M
Operating Expenses $52M$35M$23M$20M$15M$10M$11M$9M$9M$8M$14M$24M
Operating Income $-50M$-34M$-21M$-19M$-15M$-10M$-10M$-8M$-8M$-8M$-14M$-24M
Interest Expense ········$119.0K$721.0K$1M$1M
Interest Income ···········$2.0K
Other Non-op $891.0K$2M$1M$250.0K$-157.0K$-160.0K$-200.0K$-371.0K···$-1M
Pretax Income $-49M$-32M$-20M$-18M$-15M$-11M$-10M$-7M$-8M$-8M$-16M$-25M
Income Tax $63.0K$59.0K$65.0K$28.0K$45.0K$4.0K$24.0K·$27.0K$1.0K$4.0K$12.0K
Net Income $-49M$-32M$-20M$-18M$-15M$-11M$-10M$-7M$-8M$-8M$-16M$-25M
EPS (Basic) $-0.76$-0.76$-0.82$-2.35$-2.03·······
EPS (Diluted) $-0.76$-0.76$-0.82$-2.35········
Shares (Basic) 64,325,81041,928,36024,268,1817,871,8147,346,022·······
Shares (Diluted) 64,325,81041,928,36024,268,1817,871,814········
EBITDA $-50M$-34M$-21M$-19M$-15M$-10M$-10M$-7M$-8M$-8M$-14M$-23M
Balance Sheet 25
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents $9M$19M$10M$5M$12M$13M$6M$9M$4M$8M$3M$6M
Short-term Investments $45M$16M$29M·········
Receivables $2M$2M$2M$1M$1M$476.0K$823.0K$716.0K$643.0K$356.0K$405.0K$635.0K
Inventory $3M$3M$2M$2M$1M$1M$1M$1M$533.0K$500.0K$753.0K$2M
Prepaid Expense $1M$1M$578.0K$655.0K$522.0K$334.0K$87.0K$81.0K$62.0K$65.0K$75.0K$150.0K
Current Assets $61M$41M$44M$21M$37M$15M$8M$11M$5M$9M$5M$9M
PP&E (Net) $4M$2M$1M$917.0K$632.0K$448.0K$547.0K$421.0K$476.0K$379.0K$472.0K$622.0K
PP&E (Gross) $6M$5M$3M$3M$2M$2M$2M$2M$2M$1M$1M$1M
Accum. Depreciation $3M$2M$2M$2M$2M$2M$1M$1M$1M$1M$957.0K$875.0K
Intangibles ···········$752.0K
Other Non-current Assets ···········$1M
Total Assets $69M$47M$48M$25M$40M$18M$10M$12M$6M$9M$6M$11M
Accounts Payable ···········$4M
Accrued Liabilities $2M$1M$1M$554.0K$632.0K$886.0K$604.0K$903.0K$976.0K$425.0K$552.0K$993.0K
Current Liabilities $11M$8M$6M$5M$4M$4M$3M$3M$2M$5M$7M$8M
Capital Leases $2M$2M$1M$1M$781.0K$999.0K$653.0K·····
Total Liabilities $14M$11M$8M$7M$6M$6M$4M$4M$3M$5M$9M$14M
Long-term Debt ··········$5M$9M
Total Debt ·········$3M$5M·
Common Stock $4.0K$3.0K$2.0K$1.0K$1.0K······$4.0K
Paid-in Capital $357M$290M$261M$219M$217M$180M$163M$156M$143M$136M$120M·
Retained Earnings $-302M$-254M$-222M$-202M$-183M$-168M$-158M$-148M$-140M$-132M$-123M$-107M
Stockholders' Equity $55M$36M$40M$17M$34M$12M$5M$9M$3M$4M$-3M$-3M
Liabilities + Equity $69M$47M$48M$25M$40M$18M$10M$12M$6M$9M$6M$11M
Shares Outstanding 43,532,28126,611,03321,841,2158,330,9188,296,2563,284,3223,916,13438,400,0001,483,55642,653314,0654,136,852
Cash Flow 16
Metric Trend 202520242023202220212020201920182017201620152014
D&A $476M$280M$232M$188M$161.0K$151.0K$158.0K$152.0K$153.0K$142.0K$152.0K$263.0K
Stock-based Comp $12M$10M$4M$2M$2M$606.0K$325.0K$70.0K$672.0K$978.0K$3M$4M
Amort. of Intangibles ···········$148.0K
Restructuring ··········$406.0K·
Other Non-cash ·····$706.0K$-253.0K$-575.0K$-518.0K$-154.0K$641.0K$1M
Operating Cash Flow $-35M$-22M$-16M$-16M$-13M$-9M$-10M$-8M$-8M$-7M$-12M$-19M
CapEx $2M$1M$381.0K$473.0K$344.0K$88.0K$284.0K$67.0K$258.0K$49.0K$16.0K$133.0K
Investing Cash Flow $-31M$13M$-16M$8M$-22M$-187.0K$-387.0K$-44.0K$-318.0K···
Net Debt Issued ········$-2M$-3M$-4M$-1M
Stock Issued $1M$1M····$6M$16M$7M$14M$12M$10M
Net Stock Activity $1M$1M····$6M$16M$7M$14M$12M$10M
Financing Cash Flow $56M$18M$38M$-140.0K$35M$16M$6M$13M$5M···
Net Change in Cash $-10M$9M$5M$-7M$-641.0K$7M$-4M$6M$-4M$4M$-3M$-11M
Taxes Paid ·········$6.0K$13.0K·
Free Cash Flow $-37M$-23M$-17M$-16M$-14M$-9M$-10M$-8M$-8M$-8M$-12M$-19M
Levered FCF ········$-9M$-8M$-13M$-21M
Profitability 8
Metric Trend 202520242023202220212020201920182017201620152014
Gross Margin 29.5%21.5%29.1%21.6%16.8%3.3%20.3%27.6%21.2%5.4%-12.8%27.8%
Operating Margin -552.6%-478.0%-340.7%-361.9%-327.4%-417.7%-263.8%-211.4%-298.1%-403.8%-627.1%-840.9%
Net Margin -543.3%-456.6%-321.0%-357.6%-331.9%-424.3%-269.8%-201.1%-305.6%-446.7%-674.7%-890.5%
Pretax Margin -542.6%-455.8%-319.9%-357.1%-330.9%-424.1%-269.2%-201.1%-304.6%-446.7%-674.5%-890.1%
EBITDA Margin -552.6%-478.0%-340.7%-361.9%-327.4%-411.6%-259.6%-207.5%-292.6%-396.3%-616.6%-831.6%
ROA -84.0%-67.8%-55.1%-57.5%-51.9%-76.2%-90.6%-78.7%-108.8%-112.0%-200.6%-141.7%
ROE -129.3%-82.7%-48.1%-94.2%-42.3%-90.0%-151.2%-73.5%-249.2%-1539.8%885.5%-857.5%
ROIC -90.0%-93.0%-53.7%-107.7%-44.0%-85.4%-182.8%·-302.8%-113.7%-607.0%850.7%
Liquidity & Solvency 5
Metric Trend 202520242023202220212020201920182017201620152014
Current Ratio 5.75.37.34.28.54.12.53.92.11.80.71.1
Quick Ratio 5.34.76.81.13.03.52.03.51.81.60.50.8
Debt / Equity ·········0.7-1.8·
LT Debt / Equity ··········-0.4·
Interest Coverage ········-69.2-10.6-14.0-16.8
Efficiency 3
Metric Trend 202520242023202220212020201920182017201620152014
Asset Turnover 0.20.10.20.20.20.20.30.40.40.30.30.2
Inventory Turnover 2.12.42.42.92.91.82.5···2.81.2
Receivables Turnover 4.84.24.44.65.33.84.85.35.55.04.32.3
Per Share 5
Metric Trend 202520242023202220212020201920182017201620152014
Book Value / Share $1.27$1.36$1.81$2.09$4.04$0.25$1.37$0.23$1.84$2.74$-0.38$-0.07
Revenue / Share $0.14$0.17$0.26·········
Cash Flow / Share $-0.55$-0.52$-0.67·········
Cash / Share $0.21$0.71$0.44$0.56$1.45$0.26$1.41$0.24$2.50$5.09$0.42$0.15
EPS (TTM) $-0.76$-0.76$-0.82$-2.35········
Growth Rates 3
Metric Trend 202520242023202220212020201920182017201620152014
Revenue YoY 28.1%13.0%20.0%15.0%80.9%·······
Revenue CAGR 3Y 20.2%16.0%35.7%·········
Revenue CAGR 5Y 29.3%···········
Valuation (TTM) 14
Metric Trend 202520242023202220212020201920182017201620152014
Revenue TTM $9M$7M$6M$5M$4M$2M$4M$4M$3M$2M$2M$3M
Net Income TTM $-49M$-32M$-20M$-18M$-15M$-11M$-10M$-7M$-8M$-8M$-16M$-25M
Market Cap $77M$70M$61M$7M$25M$251M$63M$4.61B$5.06B$96.82B$4.43T$211.76T
Enterprise Value ·········$96.81B$4.43T·
P/E -2.3-3.5-3.4-0.4········
P/S 8.610.09.91.45.6101.117.01279.91833.951118.11919018.575144428.9
P/B 1.41.91.60.40.720.711.8526.01856.823935.2-1504729.4-75980265.7
P / Tangible Book 1.41.91.60.40.720.7······
P / Cash Flow -2.2-3.2-3.7-0.5-1.9-27.7-6.5-606.0-622.7-12917.6-382281.2-10936731.8
P / FCF -2.1-3.0-3.7-0.4-1.8-27.4-6.3-600.7-603.6-12833.7-381754.5-10862118.5
EV / EBITDA ·········-12898.1-311214.2·
EV / FCF ·········-12833.1-381754.6·
EV / Revenue ·········51115.61919019.4·
Earnings Yield -42.7%-28.9%-29.2%-273.3%········

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $9M $7M $6M $5M $4M
Gross Margin % 29.5% 21.5% 29.1% 21.6% 16.8%
Operating Margin % -552.6% -478.0% -340.7% -361.9% -327.4%
Net Income $-49M $-32M $-20M $-18M $-15M
Diluted EPS $-0.76 $-0.76 $-0.82 $-2.35 ·

Institutional owners (13F) 38 filers · $14.8M total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 38
Value held $14.8M
New positions 8
Exited positions 3
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
8 (+5 vs prior Q) 3 (-9 vs prior Q) 10 (+6 vs prior Q) 5 (-5 vs prior Q) -1.2M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
Rosalind Advisors, Inc. $2,734,411 3,905,743 18.52% Shares
Aberdeen Group plc $2,589,225 3,698,364 17.53% Shares
Nantahala Capital Management, LLC $2,363,876 3,376,484 16.01% Shares
ORBIMED ADVISORS LLC $2,193,697 3,133,405 14.85% Shares
Parkman Healthcare Partners LLC $1,691,804 2,416,518 11.46% Shares
MARSHALL WACE, LLP $1,302,284 1,860,405 8.82% Shares
Soleus Capital Management, L.P. $732,100 1,045,708 4.96% Shares
PURA VIDA INVESTMENTS, LLC $315,407 450,517 2.14% Shares
Affiance Financial, LLC $175,284 250,370 1.19% Shares
Velan Capital Investment Management LP $103,711 148,138 0.70% Shares
BlackRock, Inc. $86,108 122,993 0.58% Shares
RENAISSANCE TECHNOLOGIES LLC $78,994 112,832 0.53% Shares
Creative Planning $76,286 108,964 0.52% Shares
Schonfeld Strategic Advisors LLC $69,502 99,275 0.47% Shares
XTX Topco Ltd $34,325 49,029 0.23% Shares
Centiva Capital, LP $30,891 44,123 0.21% Shares
MILLENNIUM MANAGEMENT LLC $26,378 37,677 0.18% Shares
Mesirow Financial Investment Management, Inc. $21,003 30,000 0.14% Shares
COURIER CAPITAL LLC $21,003 30,000 0.14% Shares
MORGAN STANLEY $19,863 28,371 0.13% Shares
VESTIA PERSONAL WEALTH ADVISORS $17,100 24,425 0.12% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $14,418 20,594 0.10% Shares
LPL Financial LLC $13,037 18,621 0.09% Shares
OSAIC HOLDINGS, INC. $11,165 15,952 0.08% Shares
Avestar Capital, LLC $10,502 15,000 0.07% Shares
CITADEL ADVISORS LLC $9,521 13,600 0.06% Call option
Pallas Capital Advisors LLC $7,701 11,000 0.05% Shares
McKinley Carter Wealth Services, Inc. $7,001 10,000 0.05% Shares
AdvisorNet Financial, Inc $6,149 8,783 0.04% Shares
UBS Group AG $3,720 5,314 0.03% Shares
Farther Finance Advisors, LLC $700 1,000 0.00% Shares
SIMPLEX TRADING, LLC $521 745 0.00% Shares
INGALLS & SNYDER LLC $258 368,800 0.00% Shares
HRT FINANCIAL LP $41 59,754 0.00% Shares
Cambridge Investment Research Advisors, Inc. $14 20,166 0.00% Shares
Caitong International Asset Management Co., Ltd $1 1 0.00% Shares
CITIGROUP INC $1 1 0.00% Shares
ROYAL BANK OF CANADA $0 247 0.00% Shares

Activists & 5%+ owners 7 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Marvin Slosman April 24, 2026 5.18% Initial filing · SEC
Michael A. Lawless Oct. 29, 2025 8.60% Initial filing · SEC
Craig Shore ×2 filings Oct. 29, 2025 3.50% Amendment · SEC
Sol J. Barer ×3 filings April 20, 2016 · Initial filing · SEC
OFIR PAZ, SARA PAZ ×2 filings Jan. 28, 2014 · Initial filing Passive investment SEC
Asher Holzer ×2 filings Jan. 16, 2014 · Initial filing · SEC
OrbiMed Israel BioFund GP Limited Partnership, OrbiMed Israel GP Ltd., OrbiMed Advisors LLC, OrbiMed Capital GP IV LLC, Samuel D. Isaly April 22, 2013 · Initial filing · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 27 insiders · 13 officers · 18 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Marvin Slosman CEO and President May 12, 2026 P 3,556,658 1 0 $25,200
James J Barry President and CEO Dec. 16, 2019 A 2,166,382 0 0 $0
Alan Milinazzo President and CEO Jan. 31, 2016 F 158,718 0 0 $0
Ofir Paz CHIEF EXECUTIVE OFFICER April 8, 2011 A · 0 0 $0
Michael A. Lawless Chief Financial Officer Jan. 14, 2026 A 691,695 0 0 $0
Craig Shore CFO and CAO Jan. 7, 2025 A 1,112,460 0 0 $0
Andrea Tommasoli Chief Operating Officer Jan. 14, 2026 A 954,389 0 0 $0
Shane Thomas Gleason Chief Commercial Officer May 19, 2026 S 1,053,882 0 24 $-288,783
Patrick Verta EVP Clinical/Medical Affairs Jan. 7, 2025 A 311,532 0 0 $0
Agustin V Gago EVP, Chief Commercial Officer Oct. 24, 2016 A · 0 0 $0
Eli Bar CTO InspireMD Ltd. Jan. 26, 2015 A 342,919 0 0 $0
Eric L. Olson VP of Global Sales Operations Nov. 7, 2014 P 147,163 0 0 $0
Robert Ratini VP Sales Mkting InspireMD Ltd. June 1, 2012 A · 0 0 $0
Paul Stuka Director Sept. 18, 2026 J 667,871 14 0 $284,057
Michael Berman Director Sept. 18, 2026 J 352,586 0 0 $0
Gary S Roubin Director Sept. 18, 2026 J 834,478 1 0 $106,200
Scott R. Ward Director May 7, 2026 P 237,096 2 0 $102,637
Danny L. Dearen Director Jan. 14, 2026 A 102,047 0 0 $0
Raymond W Cohen Director Jan. 14, 2026 A 92,417 0 0 $0
Kathryn Arnold Director Dec. 30, 2025 A 303,087 0 0 $0
Thomas J Kester Director Sept. 15, 2025 A 458,573 0 0 $0
Campbell Rogers Director Oct. 13, 2021 A 27,960 0 0 $0
Sol J Barer Director Dec. 7, 2016 A 1,141,690 0 0 $0
Isaac Blech Director Dec. 7, 2016 A · 0 0 $0
James J Loughlin Director March 21, 2016 P 51,501 0 0 $0
Asher Holzer Director Nov. 26, 2013 S 1,925,110 0 0 $0
Eyal Weinstein Director May 9, 2013 A · 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 1 ETF

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
IWC · iShares Trust 0.01% 114,077 SH Sept. 10, 2026 Daily

NSPR Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 9 analysts BUY
Median target $3.00 +381.9%
2 22.2% Strong Buy
6 66.7% Buy
1 11.1% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

3 analysts · 2026-10-04

Mean target $3.33 +435.5%

← Below all targets Current price $0.62
Low$3.00 Mean$3.33 High$4.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
NSPR $77M -2.3 28.1% -543.3% -129.3% 29.5%
RXST $430M -11.0 -3.9% -29.0% -14.0% 76.6%
SKYA · · · · · ·
TELA $53M -1.4 15.8% -48.4% -501.1% 67.7%
RMTI $33M -5.5 -31.8% -7.7% -15.8% 16.9%
ADVB $15M -4.4 · · -159.1% ·
LUCY · · · · · ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 14, 2026